Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations

Over the past 15 years, three new classes of drugs, glucagon‐like peptide‐1 (GLP‐1) receptor agonists, dipeptidyl peptidase 4 (DPP‐4) inhibitors and sodium glucose cotransporter‐2 (SGLT‐2) inhibitors have been approved to treat type 2 diabetes based on effects on glycemic control. Although large ran...

Descripción completa

Detalles Bibliográficos
Autores principales: Mol, Peter G. M., Thompson, Aliza, Heerspink, Hiddo J. L., Leufkens, Hubert G. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2018
Materias:
Precision Medicine in Diabetic Kidney Disease. Guest Editor: Hiddo J. L. Heerspink
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220800/
https://www.ncbi.nlm.nih.gov/pubmed/30294953
http://dx.doi.org/10.1111/dom.13453

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220800/
https://www.ncbi.nlm.nih.gov/pubmed/30294953
http://dx.doi.org/10.1111/dom.13453

Ejemplares similares